Small Molecule, KCNQ4 Agonist ACOU085 for the Treatment & Prevention of Hearing Loss

Time: 4:15 pm
day: Day Two


• The KCNQ4 ion channel, a biologically validated drug target, plays a key role in regulating excitability and homeostasis of cochlear sensorineural cells
• This presentation highlights the otoprotective potential and development of the small molecule, clinical stage drug candidate ACOU085 for the treatment and prevention of hearing loss